Beam Therapeutics Inc.

5 days ago · prnewswire.com

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).

5 days ago · businesswire.com

LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law.

13 days ago · seekingalpha.com

Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

13 days ago · defenseworld.net

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders bought 2,316 call options on the company. This represents an increase of approximately 139% compared to the typical daily volume of 968 call options. Beam Therapeutics Trading Down 9.5% Shares of Beam Therapeutics stock opened at

14 days ago · zacks.com

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

14 days ago · seekingalpha.com

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

14 days ago · benzinga.com

Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD).

14 days ago · globenewswire.com

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies Dosing Underway in Global Pivotal Cohort Designed to Support Potential U.S. Accelerated Approval Beam to Host Investor Webcast Today, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass.

21 days ago · globenewswire.com

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam's commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

22 days ago · globenewswire.com

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: